Government subsidy for drug linked to suicide
By Cath Hart
April 13, 2007 01:00am
A CONTROVERSIAL new treatment for attention deficit hyperactivity disorder has been added to the Pharmaceutical Benefits Scheme, despite its potential to cause suicidal thoughts and stunt growth.
Health Minister Tony Abbott announced yesterday that Strattera would be added to the scheme from July 1 for the treatment of ADHD in children aged six to 18 who cannot take stimulant treatments such as methylphenidate, known as Ritalin, or dexamphetamine.
Under the PBS, the drug's price will drop from more than $100 for a month's supply to just $30.70, or $4.90 for concession-card holders.
Mr Abbott said about 18,000 people would take Strattera during its first full financial year of listing, adding about $101.2 million to PBS expenditure between 2007-08 and 2010-11.
The move comes after a Therapeutic Goods Administration assessment of Strattera last year, which identified suicidal thoughts, agitation, weight loss, chest pain and swollen testicles as potential side effects of the drug.
A spokeswoman for Strattera manufacturer Eli Lilly said drug regulation agencies in the US, Europe, Britain and Australia had all recently reviewed the safety of the drug and had reaffirmed that the drug's benefits justified the risks.
"There are benefits and risks associated with every medication," she said.
"Strattera is the most extensively studied psychiatric drug in children with the most comprehensive clinical-trials database compared to any other ADHD medication."
The head of psychological medicine at Adelaide's Women's and Children's Hospital, Jon Jureidini, said he was concerned that doctors would not exhaust other treatment options before using Strattera.
"Although it's not supported to be a first-line drug, I think we'll find that it will be used as a first-line drug, which is not what the PBAC (Pharmaceutical Benefits Advisory Committee) intended," Dr Jureidini said.
"The concerns about this drug are that it's very expensive and it's not proven to be any better than the cheaper drugs that are around and that's reflected in the determination by the PBAC, who will only financially support its use if other stimulant drugs have been tried."
Australian Medical Association vice-president Choong-Siew Yong, who specialises in child and adolescent mental health issues, said Strattera's side effects were "fairly rare" but recommended doctors and families discussed ways to monitor potential reactions in children taking the drug.
Opposition health spokeswoman Nicola Roxon said the Government needed to introduce guidelines for the diagnosis and treatment of ADHD.